Bioressant Sàrl

Bioressant is focusing on the research to relieve the world population from atopic dermatitis and eczema in a safe and long lasting way. We are developing a breakthrough, sustainable, and highly scalable technology to deliver safer, more effective skin inflammation treatments, surpassing prescription and OTC solutions in an $18B market. Our seasoned team of experts in cellular research, dermatology, strategy, and commercialization drives our innovation. Our initial dermaceuticals range, developed to test the market and support ongoing fundamental research, is now available in Swiss pharmacies and clinics, receiving excellent customer feedback.